Overview
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Alpha-0261 tablets after single oral administration in healthy adult volunteers.
Eligibility
Inclusion Criteria:
- Aged ≥ 18 and ≤ 55, male or female
- Weight: ≥ 50 kg for males, ≥ 45 kg for females; 19 kg/m2 ≤ body mass index (BMI) ≤ 28 kg/m2
- In general good health
Exclusion Criteria:
- Have a history of any severe allergic reaction or anaphylaxis
- Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
- Have clinically significant abnormalities on clinical laboratory results